Meeting
2021 ASCO Annual Meeting
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
Presenter
Xavier Garcia del Muro, MD
Medical Oncology. Institut Català d'Oncologia (ICO) L'Hospitalet del Llobregat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03702179
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4505)
DOI
10.1200/JCO.2021.39.15_suppl.4505
Abstract #
4505
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study.
Speaker: M. Andres Cuellar, MD
Speaker: Panel Discussion
Videos & Slides
2021 ASCO Annual Meeting
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
Speaker: Arjun Vasant Balar, MD
Videos & Slides
2021 Genitourinary Cancers Symposium
Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023.
Speaker: Monika Joshi, MD